Oric Pharmaceuticals

Recent news

• Company notice
  Oric Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Heyman Richard A.
  SEC · 2025/10/4
• Rating change
  Wells Fargo Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $25
  Market Newswire · 2026/6/11
• Rating change
  Goldman Sachs Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Announces Target Price $15
  Market Newswire · 2026/6/3
• H.C. Wainwright Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Raises Target Price to $27
  Market Newswire · 2026/8/10
• Rating change
  Analysts Offer Insights on Healthcare Companies: Ardent Health Partners, Inc. (ARDT), Tactile Systems Technology (TCMD) and Oric Pharmaceuticals (ORIC)
  TipRanks · 2026/6/3
• Rating change
  Oppenheimer Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $15
  Market Newswire · 2026/5/5
• Company notice
  Oric Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Heyman Richard A.
  SEC · 2026/1/7
• Rating change
  HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $25 Price Target
  Benzinga · 2026/6/8
• Company notice
  Oric Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Hoerter Steven L.
  SEC · 2026/1/7
• Rating change
  Piper Sandler Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $22
  Market Newswire · 2026/6/29
• HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $27
  Benzinga · 2026/8/10
• Company notice
  Oric Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Heyman Richard A.
  SEC · 2026/10/3
• Rating change
  Goldman Sachs Initiates Oric Pharmaceuticals(ORIC.US) With Buy Rating
  Market Newswire · 2026/5/15
• Rating change
  Stifel Initiates Oric Pharmaceuticals(ORIC.US) With Buy Rating, Announces Target Price $14
  Market Newswire · 2026/6/12
• Rating change
  Stifel Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $14
  Market Newswire · 2026/6/12
• Rating change
  H.C. Wainwright Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $25
  Market Newswire · 2026/6/24
• J.P. Morgan Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Announces Target Price $23
  Market Newswire · 2026/8/7
• BTIG Initiates Oric Pharmaceuticals(ORIC.US) With Buy Rating, Announces Target Price $26
  Market Newswire · 2026/9/23
• Company notice
  Oric Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Heyman Richard A.
  SEC · 2026/1/21
• A Quick Look at Today's Ratings for Oric Pharmaceuticals(ORIC.US), With a Forecast Between $14 to $25
  Market Newswire · 2026/8/5

Headlines are aggregated automatically and are not independently verified or edited by our team.